OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) Chemical Structure

Molecular Weight(MW): 421.49

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck.

  •  

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    OSI-906 (Linsitinib) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rzWmlEPTB;MD6wNlgxPiEQvF2= NH36O|BUSU6JRWK=
KS-1 NV7FOlR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEO4N|Uh|ryP MYfTRW5ITVJ?
TE-11 NWHMb4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDWVFlrUUN3ME2wMlA4QDJ{IN88US=> M2ez[HNCVkeHUh?=
EW-1 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG1TWM2OD1yLkC4OVg2KM7:TR?= NGqwU|FUSU6JRWK=
HMV-II NW\5e2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEi4OFYh|ryP NW\leJpoW0GQR1XS
COLO-205 M4XmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fsR2lEPTB;MD6xNFQ2PCEQvF2= M3zTO3NCVkeHUh?=
ES1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUC2PVYh|ryP NGfnbmtUSU6JRWK=
GDM-1 NYTsO2t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOwZXEyUUN3ME2wMlE{Pjd{IN88US=> M3yyOHNCVkeHUh?=
ML-2 M1nSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XRdWlEPTB;MD6xOVg6PiEQvF2= M4G5THNCVkeHUh?=
Saos-2 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHSUHZKSzVyPUCuNVY2OjZizszN MXHTRW5ITVJ?
NCI-H1355 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMUixN|Uh|ryP M3rZVXNCVkeHUh?=
G-401 NW\6XYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMUiyN{DPxE1? NYTIWpFjW0GQR1XS
EW-16 M4njNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nSppKSzVyPUCuNVg4PzdizszN M3HCbnNCVkeHUh?=
EW-7 M3ftS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjxbGZUUUN3ME2wMlE5QDhzIN88US=> M3jZSHNCVkeHUh?=
NCI-H727 NVH1b|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHiPYxKSzVyPUCuNVk4QTRizszN MoX6V2FPT0WU
LCLC-97TM1 NV\MZ2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jsNGlEPTB;MD6yNFk2PSEQvF2= MYTTRW5ITVJ?
NCI-H650 NVe4eHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMkGzPFQh|ryP M4T4Z3NCVkeHUh?=
NCI-H2122 NHfuNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITXOIlKSzVyPUCuNlMzQTlizszN NES4UXNUSU6JRWK=
SK-N-DZ MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HSN2lEPTB;MD6yN|Y6QCEQvF2= MYfTRW5ITVJ?
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\BTWM2OD1yLkK0NlQ5KM7:TR?= MmXsV2FPT0WU
LB771-HNC M3q0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkW5NVUh|ryP MXLTRW5ITVJ?
HT-144 NHLnS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P5Z2lEPTB;MD6yOlE6OSEQvF2= Mnn4V2FPT0WU
LAN-6 NE\OWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PaT2lEPTB;MD6yOlM1QCEQvF2= NIqwPY5USU6JRWK=
EW-18 M3vQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvCcVZxUUN3ME2wMlI4ODBzIN88US=> MUfTRW5ITVJ?
LS-1034 NFz2T5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rBeGlEPTB;MD6yO|E{OiEQvF2= MmnpV2FPT0WU
EW-11 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fOR2lEPTB;MD6yPFQ{OiEQvF2= NITY[Y9USU6JRWK=
SNU-C1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D4NWlEPTB;MD6yPVMyOyEQvF2= MYPTRW5ITVJ?
RS4-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7kTWM2OD1yLkOzO|U5KM7:TR?= MnjVV2FPT0WU
ES4 NHywOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu0XHhKSzVyPUCuOFExOzhizszN MU\TRW5ITVJ?
COLO-320-HSR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwNEGzOlgh|ryP MmixV2FPT0WU
NB10 NF7mOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDvSI13UUN3ME2wMlQ2PDN5IN88US=> NILjVJlUSU6JRWK=
BFTC-905 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInDb5NKSzVyPUCuOFY4PThizszN NUjkdYlOW0GQR1XS
A375 M3K0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX6TWM2OD1yLkS3OlE4KM7:TR?= MYHTRW5ITVJ?
SJRH30 NF3a[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2XoVmUUN3ME2wMlUxQDJ{IN88US=> M2f4UHNCVkeHUh?=
NOS-1 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNUKyOlch|ryP MlHVV2FPT0WU
SIG-M5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyPJhKSzVyPUCuOVM2PTdizszN MXfTRW5ITVJ?
DOK NGTtRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj4TWM2OD1yLkW1OkDPxE1? Ml34V2FPT0WU
NB69 NHTycWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi3cYZKSzVyPUCuOVgzPTdizszN MmezV2FPT0WU
SK-NEP-1 M{LXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHmRoFKSzVyPUCuOlAzOzZizszN MkXwV2FPT0WU
SK-MM-2 NFjFRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNkW0PVEh|ryP NF;vbW5USU6JRWK=
NCI-H358 NYK3NVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7VTWM2OD1yLk[3NFgzKM7:TR?= NGXyXXNUSU6JRWK=
RH-1 M3nHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD1yLke0PFU6KM7:TR?= NF\Yd3VUSU6JRWK=
NH-12 NUDr[YhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnzWHF3UUN3ME2wMlc3ODR4IN88US=> M4Llc3NCVkeHUh?=
TE-12 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwN{[0PFYh|ryP M37x[nNCVkeHUh?=
COLO-668 NWPWclA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOES2OlYh|ryP NILyVmhUSU6JRWK=
PANC-08-13 NXTVZ4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwOE[zO|ch|ryP M33J[XNCVkeHUh?=
HCC2998 M2TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4c5VKSzVyPUCuPFgzPjNizszN NITmdmJUSU6JRWK=
ABC-1 M4XWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rCNGlEPTB;MD65NFM2OiEQvF2= NW\vSFA4W0GQR1XS
ES6 NXnlV2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonMTWM2OD1yLkmxNFY3KM7:TR?= NVvCc5BxW0GQR1XS
SNU-387 NXnsZY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXTTIRUUUN3ME2wMlk6Ozl|IN88US=> MVXTRW5ITVJ?
CMK NFSxXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nYNGlEPTB;MD65PVkzQSEQvF2= NF;PPYpUSU6JRWK=
SJSA-1 NUnne4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1zLkCzOlU{KM7:TR?= NIjCUINUSU6JRWK=
SIMA NWPoZ2RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrpSIdKSzVyPUGuNFY5OjVizszN MWfTRW5ITVJ?
ES3 M2G0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ON5hKSzVyPUGuNVIzQTdizszN Mn3ZV2FPT0WU
IGROV-1 NXXEdJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLvO4toUUN3ME2xMlE2PDR2IN88US=> NWO0TpN[W0GQR1XS
MEL-JUSO NWnkOohOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4TWM2OD1zLkG1O|U6KM7:TR?= NImzWlhUSU6JRWK=
T84 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvVTWM2OD1zLkKwPVE1KM7:TR?= MUnTRW5ITVJ?
CAL-85-1 NHPVOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\RWpRRUUN3ME2xMlI{OTN6IN88US=> NGDQblhUSU6JRWK=
RD NFfQc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle5TWM2OD1zLkK2OFU2KM7:TR?= NUfEUlRmW0GQR1XS
TE-8 NV\yd483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETVb4RKSzVyPUGuN|E1PjJizszN MnvZV2FPT0WU
L-363 M2rRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHJTWM2OD1zLkO0NlA5KM7:TR?= M3\iUXNCVkeHUh?=
EKVX MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnUTWM2OD1zLkO0OVY5KM7:TR?= MWjTRW5ITVJ?
SK-MEL-3 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134XWlEPTB;MT60PFU2PiEQvF2= M3rNTnNCVkeHUh?=
TGBC24TKB MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwNUCxPVMh|ryP NGfoVG5USU6JRWK=
NCI-H1770 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorUTWM2OD1zLkWxNVE{KM7:TR?= NXjKPZhEW0GQR1XS
HuH-7 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nUWWlEPTB;MT62NFA6QCEQvF2= NH7YW|NUSU6JRWK=
HL-60 M{HxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rN[WlEPTB;MT62OlkzQCEQvF2= NWiyWohSW0GQR1XS
TE-1 M1Hse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\vVpZKSzVyPUGuO|A6PDVizszN MUjTRW5ITVJ?
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XLVGlEPTB;MT63N|g5PyEQvF2= MkLCV2FPT0WU
LB647-SCLC NUDIfVNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD1zLke2OVg{KM7:TR?= MV\TRW5ITVJ?
NCI-H2171 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zIe2lEPTB;MT63O|cyPiEQvF2= MlO4V2FPT0WU
SK-PN-DW NE\JUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrSOJdKSzVyPUGuPVEzQThizszN NVXlS|ZoW0GQR1XS
MC-IXC Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLwUGRKSzVyPUGuPVg6QCEQvF2= M33Fb3NCVkeHUh?=
LS-513 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\nb29KSzVyPUKuNFU{ODVizszN M{LIdXNCVkeHUh?=
EW-3 NWj0[2ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uwOmlEPTB;Mj6wPVg1PCEQvF2= NXTkU3JpW0GQR1XS
OPM-2 M1P1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDOc5RKSzVyPUKuNVAzKM7:TR?= M{HDSHNCVkeHUh?=
LP-1 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwMkW4NFch|ryP Mk\1V2FPT0WU
LU-134-A MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOzbHpIUUN3ME2yMlI4PyEQvF2= Ml3IV2FPT0WU
CP66-MEL NEK2WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrqNXpKSzVyPUKuNlkxOTRizszN M{T4cnNCVkeHUh?=
HCC1143 NWnZNIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS2OndKSzVyPUKuOFU{PjhizszN MXPTRW5ITVJ?
LOXIMVI NGDuW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHIeIhKSzVyPUKuOlAzOSEQvF2= Ml\5V2FPT0WU
TE-10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\pc2lEPTB;Mj63NFg{QCEQvF2= NIfD[YRUSU6JRWK=
NCI-H1882 NYCxO2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXyTWM2OD1{Lke1NlI4KM7:TR?= MWHTRW5ITVJ?
CHP-126 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjhTWM2OD1{Lke2N|E4KM7:TR?= NUHWdpZ{W0GQR1XS
NCI-H1623 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnhPIUxUUN3ME2yMlkzODJ2IN88US=> NGDrZXJUSU6JRWK=
GB-1 M2DtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHsc2pKSzVyPUKuPVM1ODRizszN NE[xUFJUSU6JRWK=
RCC10RGB M1HyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwOUWyPFEh|ryP NWLOZ|B7W0GQR1XS
NCI-H2141 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\STmlEPTB;Mj65Olg6PiEQvF2= NUDxTIloW0GQR1XS
GI-ME-N MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r0PGlEPTB;Mz6wNFU3PSEQvF2= M1[4fnNCVkeHUh?=
NCI-H526 NWPTeIUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNwMESwPFUh|ryP Mn[xV2FPT0WU
NCI-H747 NFvHNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ae2lEPTB;Mz6wOFk6OiEQvF2= MVvTRW5ITVJ?
SNU-423 M1LDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHPSFFbUUN3ME2zMlIxOzF|IN88US=> NIHiSGhUSU6JRWK=
A427 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ntVGlEPTB;Mz6yOVY6QSEQvF2= MVLTRW5ITVJ?
CAL-12T MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqPHRKSzVyPUOuOFA4OTNizszN Mn;3V2FPT0WU
LU-99A NGThPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO0[3BSUUN3ME2zMlQ4OTB3IN88US=> NIPYcVBUSU6JRWK=
MS-1 NXHYUoJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwNUO0Nlkh|ryP NGH1[INUSU6JRWK=
SK-LU-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwN{[yPVUh|ryP NFX4dI5USU6JRWK=
SW837 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\YTGFKSzVyPUOuO|Y{OzNizszN M{PJR3NCVkeHUh?=
ES8 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwOEO4O|ch|ryP Mne4V2FPT0WU
MZ2-MEL M4\2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGntemNKSzVyPUOuPVIxQDZizszN MljLV2FPT0WU
TGW NVroRoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwMEGzNVEh|ryP MWXTRW5ITVJ?
GP5d MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRwMEWzOlIh|ryP MWTTRW5ITVJ?
BB49-HNC NIrSNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRwMUWyNVMh|ryP NWDUNo1OW0GQR1XS
NB13 NEXRdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDFSVNKSzVyPUSuNlY5QDdizszN MojyV2FPT0WU
NTERA-S-cl-D1 M1P6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTlTWM2OD12LkK4OlE2KM7:TR?= M3j0XXNCVkeHUh?=
NCI-H1648 NEHZRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r0T2lEPTB;ND6yPVgyQSEQvF2= MoO3V2FPT0WU
LCLC-103H MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3Rd2ZpUUN3ME20MlMzOTl3IN88US=> M3nyPXNCVkeHUh?=
LS-411N MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTRwNES4PFUh|ryP M1WwVHNCVkeHUh?=
NCI-H1092 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz0TWM2OD12LkS1Olg4KM7:TR?= NHXIV4VUSU6JRWK=
PANC-10-05 NWXu[lNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjSRm9KSzVyPUSuOlk5PCEQvF2= NG\r[VNUSU6JRWK=
DK-MG NFqye49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLXTWM2OD12LkiwPVM{KM7:TR?= NHfqflFUSU6JRWK=
OVCAR-5 NGjud2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInsc5RKSzVyPUSuPFEzOjZizszN M4fNT3NCVkeHUh?=
CAL-39 M175bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD12Lki3Olch|ryP MYHTRW5ITVJ?
TE-441-T Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\XWmlEPTB;ND65NFU{PyEQvF2= MYTTRW5ITVJ?
MOLT-16 NIrCc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG4TWM2OD12Lkm1NlU{KM7:TR?= MljCV2FPT0WU
MCF7 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjD[GVbUUN3ME21MlE1PTF5IN88US=> NX3aTot6W0GQR1XS
CAPAN-1 NFP0blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PD[WlEPTB;NT6yOVcxPyEQvF2= M{jIU3NCVkeHUh?=
PSN1 M1TKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31epFKSzVyPUWuNlczOzVizszN M4fTTXNCVkeHUh?=
NCI-H292 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqxbXFQUUN3ME21MlMxODR2IN88US=> NH[yVnpUSU6JRWK=
CPC-N MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6TWM2OD13LkO5OFE6KM7:TR?= NWnIeZA6W0GQR1XS
DoTc2-4510 NGfFTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LsRWlEPTB;NT60OVM4OSEQvF2= M{nXXXNCVkeHUh?=
LB1047-RCC MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTVwNUW5N|Mh|ryP M3PnbXNCVkeHUh?=
MHH-ES-1 NIDXZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnve2UzUUN3ME21MlU6QTB5IN88US=> NUDjV3BKW0GQR1XS
NMC-G1 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVwN{CyNlch|ryP MWnTRW5ITVJ?
SW1710 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuO2FMUUN3ME21Mlc1PzVzIN88US=> MmnvV2FPT0WU
YAPC MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Gyb2lEPTB;NT63OlIxOSEQvF2= M3f5b3NCVkeHUh?=
22RV1 NFzDT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\KNVV2UUN3ME21MlgxODF7IN88US=> NUPaRWh6W0GQR1XS
COLO-679 NIXyNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fSSWlEPTB;NT64PFk1QCEQvF2= NGTvUoJUSU6JRWK=
TCCSUP MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD13LkmzNlU6KM7:TR?= Mke2V2FPT0WU
C2BBe1 M2Tafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LQfWlEPTB;NT65N|k4KM7:TR?= NXqwcoZRW0GQR1XS
TE-15 NX7lXHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;pUm9wUUN3ME22MlA3PjB3IN88US=> MWnTRW5ITVJ?
SCLC-21H MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HOUWlEPTB;Nj6xNFg1OyEQvF2= MnLOV2FPT0WU
EoL-1-cell MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZwMU[1OlMh|ryP NFLpUnpUSU6JRWK=
NKM-1 M2\me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDuUJZKSzVyPU[uNVY4OSEQvF2= MW\TRW5ITVJ?
NCI-H1304 NUnhemVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTZwMke0Nlgh|ryP M3XNXHNCVkeHUh?=
NB6 NHGzOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwMkm2NlIh|ryP M362NnNCVkeHUh?=
NALM-6 NHrGbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTZwM{OyN{DPxE1? MoLaV2FPT0WU
NCI-H522 NULlTY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr4TWM2OD14LkOzN|A3KM7:TR?= NWDsSGhXW0GQR1XS
MV-4-11 M{DDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZwM{ewO|kh|ryP NYXPRW9lW0GQR1XS
LB2241-RCC NVThOpVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17CdmlEPTB;Nj6zPFY3PyEQvF2= NVradJkxW0GQR1XS
NCI-H1417 NFPBd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILIdohKSzVyPU[uOFA5PDdizszN MYXTRW5ITVJ?
HT-1197 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvpXHBXUUN3ME22MlU4OTJ{IN88US=> MmfaV2FPT0WU
P30-OHK MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHuW4NKSzVyPU[uOlI4PyEQvF2= M3fue3NCVkeHUh?=
ALL-PO NXjhdZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD14LkexPVE3KM7:TR?= M{\icnNCVkeHUh?=
OVCAR-4 NXL0SWZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD14Lke1OFA2KM7:TR?= Mo\RV2FPT0WU
HCC2157 M3TrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwN{e0O|Uh|ryP NIHlTmVUSU6JRWK=
NCI-H838 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnueo1bUUN3ME22Mlk3PDlizszN MoDXV2FPT0WU
NCI-H1299 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJVWhCUUN3ME22Mlk4ODlizszN M1KzRXNCVkeHUh?=
SW954 M1PYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV62O|hRUUN3ME23MlIxODZ6IN88US=> NV23RpBuW0GQR1XS
NCI-H441 NVfBTIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPD[ndKSzVyPUeuN|QxPjVizszN NIO3OG9USU6JRWK=
SK-MEL-2 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO4TWM2OD15LkS4N|c{KM7:TR?= NUezSVZEW0GQR1XS
KARPAS-45 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jGdGlEPTB;Nz62OVkzQSEQvF2= MVrTRW5ITVJ?
CAL-54 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjXTWM2OD15LkiyPVc4KM7:TR?= M33XcXNCVkeHUh?=
KYSE-180 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T4d2lEPTB;Nz64PFk1OSEQvF2= NV\j[m1RW0GQR1XS
NCI-H187 NFHKfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jTb2lEPTB;Nz65OVk1PyEQvF2= NFn2XFdUSU6JRWK=
RT-112 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2WVZ2UUN3ME24MlA6Pjd5IN88US=> NIe0c5VUSU6JRWK=
NCI-H1437 NWTEU4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGV|lKSzVyPUiuNFk4QTVizszN NWP3WWVPW0GQR1XS
SNU-449 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m1S2lEPTB;OD6yPFI4OiEQvF2= NFTuZZJUSU6JRWK=
HCC1187 NHLRNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDx[3hNUUN3ME24MlI6OzlzIN88US=> NHL5W|dUSU6JRWK=
NCI-H2030 M{PzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPXNYNKSzVyPUiuN|c4OTRizszN M4HjbHNCVkeHUh?=
HuO-3N1 NIHwSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ftSGlEPTB;OD6zO|g1PCEQvF2= MkTWV2FPT0WU
COLO-792 NXTJb4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTCTWM2OD16LkSxOVI4KM7:TR?= MXTTRW5ITVJ?
MIA-PaCa-2 M3zXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7m[GNKUUN3ME24Mlg2PTB6IN88US=> MkTBV2FPT0WU
SK-N-FI NUPGcW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTlwMESyOUDPxE1? NH\BdpFUSU6JRWK=
MMAC-SF MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6zXINKSzVyPUmuNFk4PTFizszN MUnTRW5ITVJ?
NCI-H28 NUXmUYh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fFUmlEPTB;OT6xNFQ3QSEQvF2= MWrTRW5ITVJ?
ETK-1 NXHEe3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nTVGlEPTB;OT6yPVk4PCEQvF2= MVnTRW5ITVJ?
NCI-H1993 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDVeJlOUUN3ME25MlQ1OjZzIN88US=> NHrzXY5USU6JRWK=
no-11 NYXuPXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTlwNEexNkDPxE1? M1j0d3NCVkeHUh?=
ChaGo-K-1 M3HNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fFcGlEPTB;OT61NVU5OyEQvF2= NFKzS4dUSU6JRWK=
NCCIT M1P1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwNUOxOlkh|ryP M4\URXNCVkeHUh?=
SAS NHvPcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLkK0PEDPxE1? NFPjbIdUSU6JRWK=
A673 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3qdGd{UUN3ME2xNE4{PzB2IN88US=> MWrTRW5ITVJ?
NCI-H1522 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly1TWM2OD1zMD6zO|A4KM7:TR?= M3G1SXNCVkeHUh?=
NCI-H810 NXS1U5hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrNbFJKSzVyPUGwMlM6ODdizszN MXPTRW5ITVJ?
IST-MES1 M{LldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF25OnNKSzVyPUGwMlQ2PjRizszN MoDqV2FPT0WU
GR-ST NUDpVWxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFyLkWwNlQh|ryP MV\TRW5ITVJ?
SUP-T1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr3TWM2OD1zMD63N|E4KM7:TR?= NXzC[|V2W0GQR1XS
NB5 NVzsRWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFyLkmwNlIh|ryP NUHlOo83W0GQR1XS
MZ1-PC MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFyLkm1O|Eh|ryP NIDrcpZUSU6JRWK=
SK-CO-1 NXXaPG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUja[m9PUUN3ME2xNE46QTNzIN88US=> M1LrPXNCVkeHUh?=
Capan-2 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonaTWM2OD1zMT6zNVk5KM7:TR?= NUnKfmZzW0GQR1XS
697 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnqO40yUUN3ME2xNU43PzV5IN88US=> M37aZnNCVkeHUh?=
REH MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TXO2lEPTB;MUGuO|Q2OSEQvF2= NECzOIxUSU6JRWK=
GI-1 M3SwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLki2NVUh|ryP MlfLV2FPT0WU
BB65-RCC M1L3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP6dVNKSzVyPUGyMlA6OTZizszN MUPTRW5ITVJ?
NCI-H1651 NXG5fVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjCWlRKSzVyPUGyMlI1PzhizszN M4Psd3NCVkeHUh?=
NCI-H1618 NFfmNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH0bnI5UUN3ME2xNk4{QTd4IN88US=> MorKV2FPT0WU
NCI-H2081 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF{Lk[xOFEh|ryP M4PvUXNCVkeHUh?=
GCIY NFz1NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn1XVZKSzVyPUGyMlczOTNizszN M{XNbXNCVkeHUh?=
NY MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonkTWM2OD1zMz6wOlQ{KM7:TR?= MXzTRW5ITVJ?
PANC-03-27 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XvbWlEPTB;MUOuNFgxPyEQvF2= M3jSUHNCVkeHUh?=
BHY M4D4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF|LkKxNlEh|ryP NIW2eXJUSU6JRWK=
SK-OV-3 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvlbHdKSzVyPUGzMlM4PjNizszN NIrNS2tUSU6JRWK=
5637 NWG3NG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r1T2lEPTB;MUOuO|c2QSEQvF2= MkjyV2FPT0WU
LC-1F NILUR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonITWM2OD1zND6wN|U3KM7:TR?= NIr6UZJUSU6JRWK=
SNB75 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTCN4FPUUN3ME2xOE4xOzh|IN88US=> NX\yeVdOW0GQR1XS
CHP-212 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi3[WN2UUN3ME2xOE4xPDZ2IN88US=> NF;xT5dUSU6JRWK=
HT-1376 M1HSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm1O21GUUN3ME2xOE4yOTJ4IN88US=> MV7TRW5ITVJ?
MONO-MAC-6 NH3KV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF2LkG1NFIh|ryP MXTTRW5ITVJ?
CA46 M2j6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn6dXBZUUN3ME2xOE4yQDJ5IN88US=> Mmm4V2FPT0WU
SCC-15 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPiWIJKSzVyPUG0MlU2QDNizszN NULqbYRUW0GQR1XS
ATN-1 NU\IRVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfYV4hKSzVyPUG0MlY3OjdizszN NW\YU|htW0GQR1XS
NCI-H2405 NXjqTWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF2LkixOVch|ryP NWXQV4lqW0GQR1XS
NCI-H716 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j1[mlEPTB;MUSuPFQ6OyEQvF2= NXXyRndVW0GQR1XS
SW620 NHjWVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1zND65NFE1KM7:TR?= M4rFd3NCVkeHUh?=
NCI-H226 M1KxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD1zND65NFg2KM7:TR?= NH3ke4lUSU6JRWK=
SW962 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4XGlEPTB;MUSuPVQ{OiEQvF2= MX7TRW5ITVJ?
KYSE-150 NGDJc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF2Lkm1OUDPxE1? Mn3TV2FPT0WU
OCUB-M NUnJPVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LubmlEPTB;MUSuPVg5OyEQvF2= MnT2V2FPT0WU
ES7 M2\HXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vnb2lEPTB;MUWuNFk5PCEQvF2= MkfnV2FPT0WU
SW1463 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf4TpZFUUN3ME2xOU41OjJ|IN88US=> Ml\3V2FPT0WU
CAKI-1 NFS3T4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTxTWM2OD1zNT61N|Q3KM7:TR?= MWPTRW5ITVJ?
MKN28 M1\S[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\5RmlEPTB;MUWuOVQ4QSEQvF2= M13r[HNCVkeHUh?=
SW13 NUnmVHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjpTWM2OD1zNT62NVgh|ryP NITRVGlUSU6JRWK=
A3-KAW NWPRVoJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF3Lkm2PVch|ryP M4jjdXNCVkeHUh?=
LU-65 NUfMW5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rXUGlEPTB;MUWuPVc3QCEQvF2= NV3GR3BmW0GQR1XS
Calu-1 NXTLR4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPLUmdKSzVyPUG2MlA{PjhizszN NVW1Zo1jW0GQR1XS
ST486 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjtOJFFUUN3ME2xOk4xPDNzIN88US=> MY\TRW5ITVJ?
BB30-HNC M2TSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPpUYd{UUN3ME2xOk4yOjR4IN88US=> MoDrV2FPT0WU
EGI-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17VNWlEPTB;MU[uOFQ3KM7:TR?= NH;DdGpUSU6JRWK=
SH-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH6TWM2OD1zNj60O|MyKM7:TR?= MXnTRW5ITVJ?
MN-60 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnlc41KSzVyPUG3MlIzQTdizszN NEjCSI1USU6JRWK=
MPP-89 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1zNz6yOFU6KM7:TR?= M2TEWHNCVkeHUh?=
A2780 M4jsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OwXWlEPTB;MUeuOFE{QSEQvF2= M1q0bXNCVkeHUh?=
Daoy NILEcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF5LkS2PVUh|ryP NX7QbmcxW0GQR1XS
NCI-H2126 NX:wTlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LyV2lEPTB;MUeuOFc4OSEQvF2= NWDRUpRZW0GQR1XS
NCI-H1563 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkS5NVch|ryP M2HHSHNCVkeHUh?=
8-MG-BA MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOyXmRKSzVyPUG3MlY3PDhizszN NFjGUJVUSU6JRWK=
786-0 NHqwT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fYZ2lEPTB;MUeuPFM2OyEQvF2= MYLTRW5ITVJ?
AM-38 NEjiTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfjTWM2OD1zNz65N|A3KM7:TR?= NGrVNo5USU6JRWK=
COLO-824 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPGTWM2OD1zOD60OFM3KM7:TR?= NIfMOpNUSU6JRWK=
SK-MEL-30 NVXVcJU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\NTWM2OD1zOD61NFgzKM7:TR?= NULW[ZJIW0GQR1XS
CESS NFK2NldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn3TWM2OD1zOD63OlA6KM7:TR?= M2XkVnNCVkeHUh?=
BL-70 NYDmVnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfnTWM2OD1zOD64NVU3KM7:TR?= MXzTRW5ITVJ?
NCI-H2170 NHroNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL2TWM2OD1zOD65NVc6KM7:TR?= NGPMN|RUSU6JRWK=
HT-3 NFT5dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD1zOD65PFMh|ryP NY\U[5BXW0GQR1XS
BOKU NUPhfld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS5[phKSzVyPUG5MlA{QDFizszN MWrTRW5ITVJ?
HPAF-II NYDqW|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\QR28{UUN3ME2xPU4{ODF3IN88US=> NUHQfmFvW0GQR1XS
KGN MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonsTWM2OD1zOT60O|Y2KM7:TR?= M4rZU3NCVkeHUh?=
MC-CAR M{nvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XKSmlEPTB;MUmuOlMyOyEQvF2= M4r5fXNCVkeHUh?=
BHT-101 M4Cx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r3OGlEPTB;MUmuO|c4KM7:TR?= MoC0V2FPT0WU
SW1783 NIraV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzqXohKSzVyPUG5Mlc5ODZizszN NHPE[FFUSU6JRWK=
KP-N-YN MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrV[nprUUN3ME2yNE4xOjZ{IN88US=> M2fCXHNCVkeHUh?=
LU-165 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLXblVwUUN3ME2yNE42PTdzIN88US=> M4DaWXNCVkeHUh?=
GOTO NFiwWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmWJBKSzVyPUKwMlY1PTFizszN M3n1SHNCVkeHUh?=
EFM-19 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2TWM2OD1{MT6wO|E3KM7:TR?= NX61UplsW0GQR1XS
CTV-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDCd2REUUN3ME2yNU4yODV2IN88US=> MnizV2FPT0WU
HEL M4TmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fRN2lEPTB;MkGuOFIyPiEQvF2= MlvzV2FPT0WU
SNU-C2B MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[3TWM2OD1{MT60NlYh|ryP MlLRV2FPT0WU
ECC4 NW[2ZlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXSTWM2OD1{MT63NFch|ryP MXLTRW5ITVJ?
NEC8 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJzLkizOlgh|ryP NFfQc3VUSU6JRWK=
KMOE-2 M3rPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0b|ZKSzVyPUKxMlg6OjFizszN MWfTRW5ITVJ?
NCI-H524 NHLPfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ezc2lEPTB;MkKuNFgxQCEQvF2= NFnGfo5USU6JRWK=
WSU-NHL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3bpFKSzVyPUKyMlE2PzdizszN MljPV2FPT0WU
SF126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofaTWM2OD1{Mj6yOFY6KM7:TR?= NXGyPHFzW0GQR1XS
HOP-92 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;oUmlEPTB;MkKuN|E3PyEQvF2= M4TvcXNCVkeHUh?=
CTB-1 NID1[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ{LkS2O|ch|ryP MlTIV2FPT0WU
KYSE-270 NFfGZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\wcZp6UUN3ME2yNk46OzV5IN88US=> MkK4V2FPT0WU
SK-MEL-24 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOxTWM2OD1{Mz6xPFch|ryP NWnIWJJXW0GQR1XS
Calu-3 NYjJV3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ|LkKxNlgh|ryP NH2yR|FUSU6JRWK=
GAMG NITiU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD1{Mz6yN|Y4KM7:TR?= NUHObHhtW0GQR1XS
SW1573 M1XDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rSfWlEPTB;MkOuO|QyPSEQvF2= NHnPcJdUSU6JRWK=
MHH-NB-11 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ2LkCxPVQh|ryP NVzCOFFWW0GQR1XS
TK10 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXoWJNVUUN3ME2yOE42ODF|IN88US=> MkDlV2FPT0WU
LB373-MEL-D NULhOIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ2Lk[wOlQh|ryP MVvTRW5ITVJ?
KALS-1 NYHGemp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPJTWM2OD1{ND63N|I4KM7:TR?= NWfSSphSW0GQR1XS
HUTU-80 NGrIWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uNmlEPTB;MkWuPFA{OiEQvF2= MmTZV2FPT0WU
HuP-T3 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPPWXhVUUN3ME2yOk4yPjd2IN88US=> NYm3ZWsyW0GQR1XS
OE19 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ4LkKxOVMh|ryP MW\TRW5ITVJ?
J82 M1PVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfwdYVKSzVyPUK2MlI1PzFizszN M37DZXNCVkeHUh?=
DU-4475 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TRS2lEPTB;Mk[uN|gyQSEQvF2= MnjpV2FPT0WU
DMS-53 M2PjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDHTWM2OD1{Nj61NVM5KM7:TR?= MYHTRW5ITVJ?
COLO-741 M1;Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfT[nNKSzVyPUK2Mlg{PDRizszN MX3TRW5ITVJ?
SW48 M3e1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\WWWtKSzVyPUK2Mlg5OiEQvF2= Ml3QV2FPT0WU
IGR-1 NIHNOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDVbllKSzVyPUK2Mlk{OzRizszN M1vzbnNCVkeHUh?=
639-V MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ5LkCyOFUh|ryP MYPTRW5ITVJ?
LK-2 NIXObYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPXTIJWUUN3ME2yO{41OTRzIN88US=> NXjUPZZ6W0GQR1XS
NCI-H2347 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ5Lkm2PVkh|ryP MoPSV2FPT0WU
NCI-H2228 M{izbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\qTWM2OD1{OD6wPVA2KM7:TR?= M2XPVHNCVkeHUh?=
LS-123 NVmw[5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ6LkGyOlIh|ryP MVzTRW5ITVJ?
U031 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnRS5dVUUN3ME2yPE4zPTJizszN MVXTRW5ITVJ?
NCI-H1792 M4\uUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ6LkS3NlEh|ryP MmfVV2FPT0WU
NCI-H2087 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ6Lke1OVIh|ryP NYPJWHR1W0GQR1XS
NCI-H2342 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXUG8xUUN3ME2yPU42OjB6IN88US=> M3fHTnNCVkeHUh?=
SW626 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXhOW45UUN3ME2yPU44PTZizszN M3XicXNCVkeHUh?=
LB2518-MEL NWPrSGFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ7LkixOUDPxE1? MWfTRW5ITVJ?
RXF393 NVHRT4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zTWM2OD1|MD6wPVUzKM7:TR?= M1TXTnNCVkeHUh?=
LC4-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPqNmlpUUN3ME2zNE4{ODl{IN88US=> MWLTRW5ITVJ?
NCI-H1694 NH;Sb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ieZBKSzVyPUOwMlY3OjRizszN M1XLV3NCVkeHUh?=
K5 NHjGTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNyLkm3NFIh|ryP NY[1TZBJW0GQR1XS
HDLM-2 M2LCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPzOmJKSzVyPUOwMlk4OjVizszN MnSwV2FPT0WU
BCPAP MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH2e5h1UUN3ME2zNU45Ozd7IN88US=> MXnTRW5ITVJ?
BC-3 M{XaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zp[2lEPTB;M{KuNVQxOyEQvF2= NYP6Ro9qW0GQR1XS
LB996-RCC NF3EfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:yb|JKSzVyPUOyMlI{PThizszN NWf0WY4{W0GQR1XS
NCI-H2009 M37jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3exW2lEPTB;M{KuOFk5OSEQvF2= MkjiV2FPT0WU
HTC-C3 M2rjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD1|Mz63OVE6KM7:TR?= MmCzV2FPT0WU
LAMA-84 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOxTWM2OD1|ND60OFA4KM7:TR?= NXLDcGN[W0GQR1XS
CCRF-CEM M{HNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33ZemlEPTB;M{SuOVcyPSEQvF2= NGKwUGVUSU6JRWK=
AN3-CA M2\pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4XWlEPTB;M{WuNFU3QCEQvF2= NFTpOGRUSU6JRWK=
NCI-H1734 M2[we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN3LkK1OlEh|ryP MYjTRW5ITVJ?
Ca-Ski NFrjOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nHVmlEPTB;M{WuOFExOSEQvF2= NYmzNZhEW0GQR1XS
U-266 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSwTWM2OD1|NT62NVE1KM7:TR?= M4LSUnNCVkeHUh?=
SBC-5 NXPHcIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHES3NXUUN3ME2zOU44PzhzIN88US=> NYLNNokxW0GQR1XS
GT3TKB NYnPTHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK5OJFKSzVyPUO3MlEyPSEQvF2= NXjKT3lyW0GQR1XS
MDA-MB-175-VII NV2yOJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTpTWM2OD1|Nz6yNlQ5KM7:TR?= Ml3pV2FPT0WU
PFSK-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1|Nz6yOFM2KM7:TR?= MVXTRW5ITVJ?
IMR-5 M{TrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTZVJlKSzVyPUO3MlI1QDdizszN NFLWZnhUSU6JRWK=
Daudi NFj5XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN5LkO1PVch|ryP MWHTRW5ITVJ?
A498 M1K0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjIfZZvUUN3ME2zO{44OjF6IN88US=> MVHTRW5ITVJ?
SCC-4 NXPOW5IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H6WGlEPTB;M{euO|g1OyEQvF2= MWnTRW5ITVJ?
COLO-680N NGnsN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLQTWM2OD1|OD6yPFg2KM7:TR?= MYHTRW5ITVJ?
SK-MES-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN6LkOyNVUh|ryP MUXTRW5ITVJ?
SR M4\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nU[mlEPTB;M{iuOVQ6PSEQvF2= MV\TRW5ITVJ?
LNCaP-Clone-FGC NVT3ZnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1UYRKSzVyPUO4MlU3OzdizszN MmfHV2FPT0WU
SK-HEP-1 NXn1ZZdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364XGlEPTB;M{iuO|gzOiEQvF2= NIXpdWtUSU6JRWK=
BPH-1 NFz3UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zDXmlEPTB;M{iuPFMzQSEQvF2= NUTvW3VSW0GQR1XS
NCI-H1755 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO4WlBKSzVyPUO5MlU5OTdizszN NWnZWGx[W0GQR1XS
LXF-289 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfrTWM2OD1|OT64NFg1KM7:TR?= NXrGUpJpW0GQR1XS
SW1088 NGH6SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpTWM2OD12MD6yNVA4KM7:TR?= NVrWeJp7W0GQR1XS
MOLT-4 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDi[plKSzVyPUSwMlI6ODFizszN MlnvV2FPT0WU
AsPC-1 MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRyLkS1PFMh|ryP NX7rfm9XW0GQR1XS
HOP-62 M2nsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ThRWlEPTB;NECuOlU3QCEQvF2= MlnOV2FPT0WU
A172 M{PxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDPNIRCUUN3ME20NE45PTFzIN88US=> Mke4V2FPT0WU
SN12C MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRyLkmzPFUh|ryP NIfJR5dUSU6JRWK=
MDA-MB-231 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DLVmlEPTB;NECuPVg6QCEQvF2= MYXTRW5ITVJ?
RPMI-2650 NVPWOFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRzLkG1PVMh|ryP MWTTRW5ITVJ?
KYSE-140 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LnbWlEPTB;NEGuPFEzOyEQvF2= NGr5VpJUSU6JRWK=
KINGS-1 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHyTnBlUUN3ME20Nk41Pjl5IN88US=> M3PlNnNCVkeHUh?=
HSC-3 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXZU|dFUUN3ME20Nk43PjZzIN88US=> MlniV2FPT0WU
PC-14 NHKwRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6W3hqUUN3ME20N{4yQDh{IN88US=> NHfqN5FUSU6JRWK=
COR-L105 NWGwOYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPWc3hJUUN3ME20N{43PTB{IN88US=> NXm4[3RiW0GQR1XS
BE-13 NXjROJBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fGUmlEPTB;NESuNlM4OSEQvF2= Ml\KV2FPT0WU
NCI-H661 NIrCSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTR2LkK5OVgh|ryP MljVV2FPT0WU
IST-MEL1 NH;l[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzkXFRUUUN3ME20OE4{PTl7IN88US=> MnS5V2FPT0WU
HCC1806 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD5TWM2OD12ND61PFc{KM7:TR?= NVzMS4FVW0GQR1XS
COLO-800 M1vyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[zN4hOUUN3ME20OE45PDV|IN88US=> M4XIeHNCVkeHUh?=
IST-SL2 M1jKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{niZWlEPTB;NEWuNVI1PyEQvF2= NH;2RpdUSU6JRWK=
8305C NETRWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzTVnFKSzVyPUS1MlMxQSEQvF2= NV3ifGlGW0GQR1XS
UACC-62 M4r0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvMXpNKSzVyPUS2MlI5PzVizszN NVv5O|BPW0GQR1XS
COR-L23 M2Hxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3MUWRKSzVyPUS3MlE6QSEQvF2= NVXBWo5YW0GQR1XS
EFE-184 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR5LkO4PEDPxE1? MnHWV2FPT0WU
DMS-114 NVTkeYltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K0ZmlEPTB;NEeuOFE1QSEQvF2= MU\TRW5ITVJ?
KYSE-520 NGS4[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrU[GZxUUN3ME20PE42OzF3IN88US=> MXTTRW5ITVJ?
SNG-M M3HXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfMTWM2OD12OT60N|Qh|ryP NWHrZZhvW0GQR1XS
A2058 M1;rPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvIU49DUUN3ME20PU41QDh3IN88US=> MXvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID